In sum, our data nominate CDC7 as a therapeutic target (1) to constrain plasticity and NE transformation as a mechanism of acquired resistance to targeted therapies in lung and prostate cancers; and (2) to induce sensitivity to cytotoxic therapy and extend response to treatment in lung and prostate NE tumors. Here, CDC7 is linked to Familial prostate cancer.